Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma
Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2293 |
id |
doaj-7ea88f54092644f5b48cce4a6ddadffc |
---|---|
record_format |
Article |
spelling |
doaj-7ea88f54092644f5b48cce4a6ddadffc2020-11-25T03:56:50ZengMDPI AGCancers2072-66942020-08-01122293229310.3390/cancers12082293Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell LymphomaAuris Huen0Bradley M. Haverkos1Jasmine Zain2Ramchandren Radhakrishnan3Mary Jo Lechowicz4Sumana Devata5Neil J. Korman6Lauren Pinter-Brown7Yasuhiro Oki8Prajak J. Barde9Ajit Nair10Kasi Viswanath Routhu11Srikant Viswanadha12Swaroop Vakkalanka13Swaminathan P. Iyer14Department of Dermatology, the University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Medicine, Division of Hematology, University of Colorado, Denver, CO 80204, USADepartment of Lymphoma, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USADepartment of Lymphoma, the University of Tennessee Graduate School of Medicine, Knoxville, TN 37920, USADepartment of Lymphoma, Emory University, Atlanta, GA 30322, USAMedical College of Wisconsin. Previously with Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USADepartment of Dermatology, Case Western Reserve University and University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USADepartment of Medicine and Dermatology, Chao Family Comprehensive Cancer Center University of California, Irvine, CA 92868, USAGenentech Inc. Previously with Department of Lymphoma and Myeloma, the University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USARhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, SwitzerlandRhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, SwitzerlandRhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, SwitzerlandRhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, SwitzerlandRhizen Pharmaceuticals S.A., CH-2300 La Chaux-de-Fonds, SwitzerlandDepartment of Lymphoma and Myeloma, the University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USATenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥1 prior therapy received Tenalisib orally in a 28-day cycle in doses of 200 to 800 mg twice daily (800 mg in fasting and fed state) in escalation phase (<i>n</i> = 19) and 800 mg twice daily (fasting) in expansion phase (<i>n</i> = 39). The most frequently reported treatment emergent adverse events (TEAE) and related TEAE were fatigue (45%) and transaminase elevations (33%), respectively. Most frequently reported related Grade ≥3 TEAE was transaminase elevation (21%). Two dose-limiting toxicities occurred in the 800 mg fed cohort; hence, 800 mg fasting dose was deemed MTD. Tenalisib was absorbed rapidly with a median half-life of 2.28 h. Overall response rate in 35 evaluable patients was 45.7% (3 complete response (CR); 13 partial response (PR)) and median duration of response was 4.9 months. Responding tumors showed a marked downregulation of CD30, IL-31 and IL-32α. With an acceptable safety and promising clinical activity, Tenalisib can be a potential therapeutic option for relapsed/refractory TCL. Currently, a phase I/II combination study with romidepsin is ongoing.https://www.mdpi.com/2072-6694/12/8/2293maximum tolerated dosedose limiting toxicityPTCLCTCL |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Auris Huen Bradley M. Haverkos Jasmine Zain Ramchandren Radhakrishnan Mary Jo Lechowicz Sumana Devata Neil J. Korman Lauren Pinter-Brown Yasuhiro Oki Prajak J. Barde Ajit Nair Kasi Viswanath Routhu Srikant Viswanadha Swaroop Vakkalanka Swaminathan P. Iyer |
spellingShingle |
Auris Huen Bradley M. Haverkos Jasmine Zain Ramchandren Radhakrishnan Mary Jo Lechowicz Sumana Devata Neil J. Korman Lauren Pinter-Brown Yasuhiro Oki Prajak J. Barde Ajit Nair Kasi Viswanath Routhu Srikant Viswanadha Swaroop Vakkalanka Swaminathan P. Iyer Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma Cancers maximum tolerated dose dose limiting toxicity PTCL CTCL |
author_facet |
Auris Huen Bradley M. Haverkos Jasmine Zain Ramchandren Radhakrishnan Mary Jo Lechowicz Sumana Devata Neil J. Korman Lauren Pinter-Brown Yasuhiro Oki Prajak J. Barde Ajit Nair Kasi Viswanath Routhu Srikant Viswanadha Swaroop Vakkalanka Swaminathan P. Iyer |
author_sort |
Auris Huen |
title |
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma |
title_short |
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma |
title_full |
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma |
title_fullStr |
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma |
title_full_unstemmed |
Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma |
title_sort |
phase i/ib study of tenalisib (rp6530), a dual pi3k δ/γ inhibitor in patients with relapsed/refractory t-cell lymphoma |
publisher |
MDPI AG |
series |
Cancers |
issn |
2072-6694 |
publishDate |
2020-08-01 |
description |
Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous T-Cell Lymphoma (TCL). Histologically confirmed (TCL) patients, with ≥1 prior therapy received Tenalisib orally in a 28-day cycle in doses of 200 to 800 mg twice daily (800 mg in fasting and fed state) in escalation phase (<i>n</i> = 19) and 800 mg twice daily (fasting) in expansion phase (<i>n</i> = 39). The most frequently reported treatment emergent adverse events (TEAE) and related TEAE were fatigue (45%) and transaminase elevations (33%), respectively. Most frequently reported related Grade ≥3 TEAE was transaminase elevation (21%). Two dose-limiting toxicities occurred in the 800 mg fed cohort; hence, 800 mg fasting dose was deemed MTD. Tenalisib was absorbed rapidly with a median half-life of 2.28 h. Overall response rate in 35 evaluable patients was 45.7% (3 complete response (CR); 13 partial response (PR)) and median duration of response was 4.9 months. Responding tumors showed a marked downregulation of CD30, IL-31 and IL-32α. With an acceptable safety and promising clinical activity, Tenalisib can be a potential therapeutic option for relapsed/refractory TCL. Currently, a phase I/II combination study with romidepsin is ongoing. |
topic |
maximum tolerated dose dose limiting toxicity PTCL CTCL |
url |
https://www.mdpi.com/2072-6694/12/8/2293 |
work_keys_str_mv |
AT aurishuen phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT bradleymhaverkos phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT jasminezain phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT ramchandrenradhakrishnan phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT maryjolechowicz phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT sumanadevata phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT neiljkorman phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT laurenpinterbrown phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT yasuhirooki phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT prajakjbarde phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT ajitnair phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT kasiviswanathrouthu phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT srikantviswanadha phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT swaroopvakkalanka phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma AT swaminathanpiyer phaseiibstudyoftenalisibrp6530adualpi3kdginhibitorinpatientswithrelapsedrefractorytcelllymphoma |
_version_ |
1724463552505315328 |